Eli Lilly and Company today announced the launch of Lilly TuneLab, an artificial intelligence and machine learning (AI/ML) platform that provides biotech companies access to drug discovery models trained on years of Lilly’s research data. Lilly estimates that this first release of AI models includes proprietary data obtained at a cost of over $1 billion, representing one of the industry’s most valuable datasets used to train an AI system available to biotechnology companies. “Lilly has spent decades building comprehensive datasets for drug discovery. Today, we’re sharing the intelligence gained from that investment to help lift the tide of biotechnology research,” said Daniel Skovronsky, M.D., Ph.D., chief scientific officer, and president, Lilly Research Laboratories and Lilly Immunology. “Lilly TuneLab was created to be an equalizer so that smaller companies can access some of the same AI capabilities used every day by Lilly scientists. By opening up access, we hope to accelerate the creation of new medicines for patients who need them.” Lilly TuneLab is powered by Lilly’s full drug disposition, safety, and preclinical datasets representing experimental data obtained with hundreds of thousands of unique molecules.

Full report : Lilly launches TuneLab platform to give biotechnology companies access to AI-enabled drug discovery models built through over $1 billion in research investment.